These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 8131613)
1. Clinical sepsis trials. Abraham E Chest; 1994 Mar; 105(3 Suppl):53S-55S. PubMed ID: 8131613 [No Abstract] [Full Text] [Related]
2. Targets for sepsis therapies: tumor necrosis factor versus interleukin-1. Russell DA; Thompson RC Curr Opin Biotechnol; 1993 Dec; 4(6):714-21. PubMed ID: 7764470 [TBL] [Abstract][Full Text] [Related]
3. Treatment of septic shock with immunotherapy. Smith AL Pharmacotherapy; 1998; 18(3):565-80. PubMed ID: 9620107 [TBL] [Abstract][Full Text] [Related]
4. [Monoclonal antibodies in the treatment of sepsis and septic shock]. Torrabadella de Reynoso P; Salgado Remigio A; Peracaula Picart R Med Clin (Barc); 1992 Dec; 99(20):784-92. PubMed ID: 1460952 [No Abstract] [Full Text] [Related]
5. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock. Calandra T; Baumgartner JD; Glauser MP Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424 [TBL] [Abstract][Full Text] [Related]
6. Very large-scale, randomized, clinical trials in sepsis and septic shock. Solomkin JS Crit Care Med; 1994 Jan; 22(1):1-2. PubMed ID: 8124949 [No Abstract] [Full Text] [Related]
7. Sepsis trials. Intersection of investigation, regulation, funding, and practice. Bernard GR Am J Respir Crit Care Med; 1995 Jul; 152(1):4-10. PubMed ID: 7599855 [No Abstract] [Full Text] [Related]
8. Plasmapheresis as part of the treatment for septic shock. Hjorth V; Stenlund G Scand J Infect Dis; 2000; 32(5):511-4. PubMed ID: 11055656 [TBL] [Abstract][Full Text] [Related]
9. New therapies in sepsis. Vincent JL Chest; 1997 Dec; 112(6 Suppl):330S-338S. PubMed ID: 9400898 [No Abstract] [Full Text] [Related]
10. Potential strategies for inflammatory mediator manipulation: retrospect and prospect. Fisher CJ; Zheng Y World J Surg; 1996 May; 20(4):447-53. PubMed ID: 8662133 [TBL] [Abstract][Full Text] [Related]
12. Current status of clinical trials with anti-TNF. Porter SB Chest; 1997 Dec; 112(6 Suppl):339S-341S. PubMed ID: 9400899 [No Abstract] [Full Text] [Related]
13. Adjunctive therapy for septic shock: a review of experimental approaches. Lynn WA; Cohen J Clin Infect Dis; 1995 Jan; 20(1):143-58. PubMed ID: 7727640 [TBL] [Abstract][Full Text] [Related]
14. Antiendotoxin antibodies: a dead end? Cross AS Ann Intern Med; 1994 Jul; 121(1):58-60. PubMed ID: 8198349 [No Abstract] [Full Text] [Related]
15. Immunological therapy of sepsis: experimental therapies. Arndt P; Abraham E Intensive Care Med; 2001; 27 Suppl 1():S104-15. PubMed ID: 11307366 [No Abstract] [Full Text] [Related]
16. Interleukin-1, TNF alpha and their naturally occurring antagonists in sepsis. Moldawer LL Blood Purif; 1993; 11(2):128-33. PubMed ID: 8274244 [TBL] [Abstract][Full Text] [Related]
17. Therapies for sepsis. Emerging therapies for sepsis and septic shock. Abraham E West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195 [No Abstract] [Full Text] [Related]
18. Researchers try new definitions, new therapies in effort to solve growing problem of sepsis. Skolnick AA JAMA; 1993 Feb; 269(7):838-9, 843. PubMed ID: 8426434 [No Abstract] [Full Text] [Related]
19. [Acute renal failure in sepsis. Strategies for prevention]. Hausmann R Aktuelle Urol; 2005 Jun; 36(3):188-94. PubMed ID: 16001335 [No Abstract] [Full Text] [Related]
20. [Immunotherapy in sepsis syndrome]. Schellekens JF; van Deventer SJ Ned Tijdschr Geneeskd; 1992 May; 136(22):1050-4. PubMed ID: 1603159 [No Abstract] [Full Text] [Related] [Next] [New Search]